Hims & Hers Health (NYSE:HIMS) Stock Price Down 5.8% – Time to Sell?

Hims & Hers Health, Inc. (NYSE:HIMS) dropped 5.8% during trading on Wednesday . The stock traded as low as $30.01 and last traded at $29.8960. Approximately 4,631,262 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 25,859,250 shares. The stock had previously closed at $31.75.

Trending Headlines about Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Truist reportedly issued a bullish outlook for Hims & Hers’ weight-loss business, suggesting that GLP-1-related revenue could provide a substantial growth avenue. Hims & Hers Stock Rises on Bullish Weight-Loss Revenue Forecast from Truist
• Positive Sentiment: Analyst commentary describes Hims & Hers as expanding beyond its original telehealth model into a broader consumer-health platform, supporting the longer-term growth narrative. Hims & Hers Is Growing Into Something Much Bigger
• Positive Sentiment: The company’s most recently reported quarter showed revenue of $753.2 million, up 38.2% year over year and ahead of consensus, although profitability fell short of expectations.
• Neutral Sentiment: Recent analysis of Hims & Hers’ quarterly results highlights strong growth relative to healthcare-technology peers, while also emphasizing the need to improve earnings and margins. Unpacking Q2 Earnings: Hims & Hers Health in Context of Other Healthcare Technology Stocks
• Negative Sentiment: The Federal Trade Commission, along with two states, is targeting alleged health-data sharing, subscription, billing and cancellation practices. The allegations could create compliance costs, reputational damage and potential financial penalties. FTC, Two States Take Aim at Hims & Hers’ Subscription and Health-Data Practices
• Negative Sentiment: Multiple law firms—including Pomerantz, Kaplan Fox, Hagens Berman and Berger Montague—are investigating potential securities-law violations or breaches of fiduciary duty related to the allegations. These announcements increase headline and litigation risk, although they do not establish wrongdoing. Pomerantz Investor Alert
• Negative Sentiment: A recent analyst downgrade and the FTC-related developments have amplified volatility and pressured the stock’s valuation, despite bullish expectations for weight-loss sales. Hims & Hers Shares Gap Down Following Analyst Downgrade

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Needham & Company LLC boosted their price objective on shares of Hims & Hers Health from $35.00 to $42.00 and gave the stock a “buy” rating in a research note on Tuesday, August 11th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. BTIG Research restated a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Canaccord Genuity Group upped their price target on shares of Hims & Hers Health from $32.00 to $40.00 and gave the stock a “buy” rating in a research report on Wednesday, July 1st. Finally, JPMorgan Chase & Co. lowered their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Four investment analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $32.50.

Hims & Hers Health Price Performance

The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The company’s 50-day simple moving average is $32.27 and its 200-day simple moving average is $26.33. The company has a market cap of $7.38 billion, a price-to-earnings ratio of -50.20 and a beta of 2.40.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). The firm had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company’s revenue for the quarter was up 38.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.17 EPS.

Insider Activity

In other Hims & Hers Health news, insider Soleil Boughton sold 25,111 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the transaction, the insider owned 313,964 shares in the company, valued at $8,649,708.20. The trade was a 7.41% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 14,027 shares of the company’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total transaction of $441,850.50. Following the completion of the transaction, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 186,769 shares of company stock worth $6,035,648 over the last three months. 11.76% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of HIMS. Corient Private Wealth LP grew its stake in Hims & Hers Health by 38.3% during the 2nd quarter. Corient Private Wealth LP now owns 22,727 shares of the company’s stock valued at $788,000 after purchasing an additional 6,288 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in Hims & Hers Health during the 2nd quarter worth approximately $1,030,000. California State Teachers Retirement System raised its position in shares of Hims & Hers Health by 3,404.9% in the 2nd quarter. California State Teachers Retirement System now owns 8,000,068 shares of the company’s stock valued at $277,362,000 after purchasing an additional 7,771,816 shares in the last quarter. Ameritas Advisory Services LLC raised its position in shares of Hims & Hers Health by 12.8% in the 2nd quarter. Ameritas Advisory Services LLC now owns 17,965 shares of the company’s stock valued at $623,000 after purchasing an additional 2,045 shares in the last quarter. Finally, Compass Financial Management LLC purchased a new position in shares of Hims & Hers Health during the 2nd quarter valued at approximately $50,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.